8 November 2022FeaturesMuireann Bolger

Sea change: a Q&A with Kathi Vidal

You have always been a proponent of diversity and inclusion. What drove you to make that an area of focus?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Pharma

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.

Pharma

MSD’s Keytruda hit by eight-country ban across Europe

8 October 2026 Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.

Careers

Foley Hoag adds two partners in Denver expansion

8 October 2026 The firm has snapped up IP partners from Sheridan Ross as it ramps up its presence in Denver and targets growing demand from life sciences and technology clients.

More features

Lilly loses Fed Circ rehearing bid, sparking enablement questions

Conley Rose welcomes back former employee with legal and business nous

Beyond the primary patent: How pharma can build competitive barriers

Sun Pharma import ban back in force after Squires intervention

Former USPTO acting director takes the helm at C4IP

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

The UPC plugs another gap in its procedural rulebook

Sea change: a Q&A with Kathi Vidal

More on this story

Editor's picks

Editor's picks

More features